232 related articles for article (PubMed ID: 33035330)
1. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.
Luque Paz D; Jouanneau-Courville R; Riou J; Ianotto JC; Boyer F; Chauveau A; Renard M; Chomel JC; Cayssials E; Gallego-Hernanz MP; Pastoret C; Murati A; Courtier F; Rousselet MC; Quintin-Roué I; Cottin L; Orvain C; Thépot S; Chrétien JM; Delneste Y; Ifrah N; Blanchet O; Hunault-Berger M; Lippert E; Ugo V
Blood Adv; 2020 Oct; 4(19):4887-4897. PubMed ID: 33035330
[TBL] [Abstract][Full Text] [Related]
2. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia.
Gaidano G; Pastore C; Santini V; Nomdedeu J; Gamberi B; Capello D; Vischia F; Resegotti L; Mazza U; Ferrini PR; Lo Coco F; Saglio G
Genes Chromosomes Cancer; 1997 Aug; 19(4):250-5. PubMed ID: 9258660
[TBL] [Abstract][Full Text] [Related]
3. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
4. Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective.
Rontauroli S; Carretta C; Parenti S; Bertesi M; Manfredini R
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499582
[TBL] [Abstract][Full Text] [Related]
5. Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia.
Morishita S; Hashimoto Y; Furuya C; Edahiro Y; Ochiai T; Shirane S; Inano T; Yasuda H; Ando M; Araki M; Komatsu N
Eur J Haematol; 2023 Feb; 110(2):131-136. PubMed ID: 36208190
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
7. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
[TBL] [Abstract][Full Text] [Related]
8. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
10. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
11. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
12. Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.
Luque Paz D; Chauveau A; Boyer F; Buors C; Samaison L; Cottin L; Seegers V; Férec C; Le Maréchal C; Gueguen P; Lippert E; Ianotto JC; Ugo V
Genes Chromosomes Cancer; 2017 May; 56(5):354-362. PubMed ID: 27997717
[TBL] [Abstract][Full Text] [Related]
13. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
Higuchi T; Okada S; Mori H; Niikura H; Omine M; Terada H
Cancer; 1995 Jan; 75(2):471-7. PubMed ID: 7812918
[TBL] [Abstract][Full Text] [Related]
14. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
[TBL] [Abstract][Full Text] [Related]
15. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
17. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
18. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
19. A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Hernández-Boluda JC; Pereira A; Cervantes F; Alvarez-Larrán A; Collado M; Such E; Arilla MJ; Boqué C; Xicoy B; Maffioli M; Bellosillo B; Marugán I; Amat P; Besses C; Guillem V
Blood; 2012 May; 119(22):5221-8. PubMed ID: 22496165
[TBL] [Abstract][Full Text] [Related]
20. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
